Skip to main content
SpringerLink
Log in
Book cover

Diagnosis and Management of Polycystic Ovary Syndrome pp 209–232Cite as

Medical Treatment

  • Chapter
  • First Online:

The polycystic ovary syndrome (PCOS) is a very common disorder, affecting 6–10% of women of reproductive age [1–5], that significantly reduces the quality of life of affected women [6–11] and greatly increases the risk for the metabolic syndrome [12–14], type 2 diabetes [15–23] and probably cardiovascular diseases [14,24–31]. It is therefore not only an infertility or cosmetic issue but also a disabling condition with serious long-term consequences. In order to provide the best quality of care, physicians should consider both immediate and long-term issues when managing women with PCOS.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   139.00
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

References

  1. Asuncion M, Calvo RM, San Millan JL, Sancho J, Avila S, Escobar-Morreale HF. A prospective study of the prevalence of the polycystic ovary syndrome in unselected Caucasian women from Spain. J Clin Endocrinol Metab 2000; 85(7):2434–2438.

    Article  PubMed  CAS  Google Scholar 

  2. Knochenhauer ES, Key TJ, Kahsar-Miller M, Waggoner W, Boots LR, Azziz R. Prevalence of the polycystic ovary syndrome in unselected black and white women of the southeastern United States: a prospective study. J Clin Endocrinol Metab 1998; 83(9):3078–3082.

    Article  PubMed  CAS  Google Scholar 

  3. Diamanti-Kandarakis E, Kouli CR, Bergiele AT, Filandra FA, Tsianateli TC, Spina GG et al. A survey of the polycystic ovary syndrome in the Greek island of Lesbos: hormonal and metabolic profile. J Clin Endocrinol Metab 1999; 84(11):4006–4011.

    Article  PubMed  CAS  Google Scholar 

  4. Michelmore KF, Balen AH, Dunger DB, Vessey MP. Polycystic ovaries and associated clinical and biochemical features in young women. Clin Endocrinol (Oxf) 1999; 51(6):779–786.

    Article  CAS  Google Scholar 

  5. Azziz R, Woods KS, Reyna R, Key TJ, Knochenhauer ES, Yildiz BO. The Prevalence and Features of the Polycystic Ovary Syndrome in an Unselected Population. J Clin Endocrinol Metab 2004; 89(6):2745–2749.

    Article  PubMed  CAS  Google Scholar 

  6. Coffey S, Mason H. The effect of polycystic ovary syndrome on health-related quality of life. [Review] [72 refs]. Gynecol Endocrinol 2003; 17(5):379–386.

    Article  PubMed  CAS  Google Scholar 

  7. Elsenbruch S, Hahn S, Kowalsky D, Offner AH, Schedlowski M, Mann K et al. Quality of life, psychosocial well-being, and sexual satisfaction in women with polycystic ovary syndrome. J Clin Endocrinol Metab 2003; 88(12):5801–5807.

    Article  PubMed  CAS  Google Scholar 

  8. Hahn S, Janssen OE, Tan S, Pleger K, Mann K, Schedlowski M et al. Clinical and psychological correlates of quality-of-life in polycystic ovary syndrome. Eur J Endocrinol 2005; 153(6):853–860.

    Article  PubMed  CAS  Google Scholar 

  9. McCook JG, Reame NE, Thatcher SS. Health-related quality of life issues in women with polycystic ovary syndrome. J Obstet Gynecol Neonatal Nurs 2005; 34(1):12–20.

    Article  PubMed  Google Scholar 

  10. Trent ME, Rich M, Austin SB, Gordon CM. Fertility concerns and sexual behavior in adolescent girls with polycystic ovary syndrome: implications for quality of life. Journal of Pediatric & Adolescent Gynecology 2003; 16(1):33–37.

    Article  Google Scholar 

  11. Trent ME, Rich M, Austin SB, Gordon CM. Quality of life in adolescent girls with polycystic ovary syndrome. Archives of Pediatrics & Adolescent Medicine 2002; 156(6):556–560.

    Google Scholar 

  12. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001; 285(19): 2486–2497.

    Article  Google Scholar 

  13. Glueck CJ, Papanna R, Wang P, Goldenberg N, Sieve-Smith L. Incidence and treatment of metabolic syndrome in newly referred women with confirmed polycystic ovarian syndrome. Metabolism 2003; 52(7):908–915.

    Article  PubMed  CAS  Google Scholar 

  14. Vural B, Caliskan E, Turkoz E, Kilic T, Demirci A. Evaluation of metabolic syndrome frequency and premature carotid atherosclerosis in young women with polycystic ovary syndrome. Hum Reprod 2005; 20(9):2409–2413.

    Article  PubMed  Google Scholar 

  15. Gambineri A, Pelusi C, Manicardi E, Vicennati V, Cacciari M, Morselli-Labate AM et al. Glucose intolerance in a large cohort of mediterranean women with polycystic ovary syndrome: phenotype and associated factors. Diabetes 2004; 53(9): 2353–2358.

    Article  PubMed  CAS  Google Scholar 

  16. Weerakiet S, Srisombut C, Bunnag P, Sangtong S, Chuangsoongnoen N, Rojanasakul A. Prevalence of type 2 diabetes mellitus and impaired glucose tolerance in Asian women with polycystic ovary syndrome. Int J Gynaecol Obstet 2001; 75(2): 177–184.

    Article  PubMed  CAS  Google Scholar 

  17. Legro RS, Kunselman AR, Dodson WC, Dunaif A. Prevalence and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome: a prospective, controlled study in 254 affected women. J Clin Endocrinol Metab 1999; 84(1):165–169.

    Article  PubMed  CAS  Google Scholar 

  18. Ehrmann DA, Barnes RB, Rosenfield RL, Cavaghan MK, Imperial J. Prevalence of impaired glucose tolerance and diabetes in women with polycystic ovary syndrome. Diabetes Care 1999; 22(1):141–146.

    Article  PubMed  CAS  Google Scholar 

  19. Palmert MR, Gordon CM, Kartashov AI, Legro RS, Emans SJ, Dunaif A. Screening for abnormal glucose tolerance in adolescents with polycystic ovary syndrome. J Clin Endocrinol Metab 2002; 87(3):1017–1023.

    Article  PubMed  CAS  Google Scholar 

  20. Legro RS, Gnatuk CL, Kunselman AR, Dunaif A. Changes in glucose tolerance over time in women with polycystic ovary syndrome: A controlled study. J Clin Endocrinol Metab 2005; 90(6):3236–3242.

    Article  PubMed  CAS  Google Scholar 

  21. Solomon CG, Hu FB, Dunaif A, Rich-Edwards J, Willett WC, Hunter DJ et al. Long or highly irregular menstrual cycles as a marker for risk of type 2 diabetes mellitus. JAMA 2001; 286(19):2421–2426.

    Article  PubMed  CAS  Google Scholar 

  22. Peppard HR, Marfori J, Iuorno MJ, Nestler JE. Prevalence of polycystic ovary syndrome among premenopausal women with type 2 diabetes. Diabetes Care 2001; 24(6):1050–1052.

    Article  PubMed  CAS  Google Scholar 

  23. Conn JJ, Jacobs HS, Conway GS. The prevalence of polycystic ovaries in women with type 2 diabetes mellitus. Clin Endocrinol (Oxf) 2000; 52(1):81–86.

    Article  CAS  Google Scholar 

  24. Lakhani K, Hardiman P, Seifalian AM. Intima-media thickness of elastic and muscular arteries of young women with polycystic ovaries. Atherosclerosis 2004; 175(2):353–359.

    Article  PubMed  CAS  Google Scholar 

  25. Talbott EO, Zborowski JV, Rager JR, Boudreaux MY, Edmundowicz DA, Guzick DS. Evidence for an association between metabolic cardiovascular syndrome and coronary and aortic calcification among women with polycystic ovary syndrome. J Clin Endocrinol Metab 2004; 89(11):5454–5461.

    Article  PubMed  CAS  Google Scholar 

  26. Talbott EO, Guzick DS, Sutton-Tyrrell K, McHugh-Pemu KP, Zborowski JV, Remsberg KE et al. Evidence for association between polycystic ovary syndrome and premature carotid atherosclerosis in middle-aged women. Arterioscler Thromb Vasc Biol 2000; 20(11):2414–2421.

    Article  PubMed  CAS  Google Scholar 

  27. Shroff R, Kerchner A, Maifeld M, Van Beek EJ, Jagasia D, Dokras A. Young obese women with polycystic ovary syndrome have evidence of early coronary atherosclerosis. J Clin Endocrinol Metab 2007; 92(12):4609–4614.

    Article  PubMed  CAS  Google Scholar 

  28. Cascella T, Palomba S, De S, I, Manguso F, Giallauria F, De Simone B et al. Visceral fat is associated with cardiovascular risk in women with polycystic ovary syndrome. Hum Reprod 2008; 23(1):153–159.

    Google Scholar 

  29. Orio F, Jr., Palomba S, Cascella T, De Simone B, Di Biase S, Russo T et al. Early impairment of endothelial structure and function in young normal-weight women with polycystic ovary syndrome. J Clin Endocrinol Metab 2004; 89(9): 4588–4593.

    Article  PubMed  CAS  Google Scholar 

  30. Cibula D, Cifkova R, Fanta M, Poledne R, Zivny J, Skibova J. Increased risk of non-insulin dependent diabetes mellitus, arterial hypertension and coronary artery disease in perimenopausal women with a history of the polycystic ovary syndrome. Hum Reprod 2000; 15(4):785–789.

    Article  PubMed  CAS  Google Scholar 

  31. Solomon CG, Hu FB, Dunaif A, Rich-Edwards JE, Stampfer MJ, Willett WC et al. Menstrual cycle irregularity and risk for future cardiovascular disease. J Clin Endocrinol Metab 2002; 87(5):2013–2017.

    Article  PubMed  CAS  Google Scholar 

  32. DeFronzo RA, Tobin JD, Andres R. Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol 1979; 237(3):E214–E223.

    PubMed  CAS  Google Scholar 

  33. Dunaif A, Segal KR, Futterweit W, Dobrjansky A. Profound peripheral insulin resistance, independent of obesity, in polycystic ovary syndrome. Diabetes 1989; 38(9):1165–1174.

    Article  PubMed  CAS  Google Scholar 

  34. Dunaif A. Insulin action in the polycystic ovary syndrome. Endocrinology & Metabolism Clinics of North America 1999; 28(2):341–359.

    Article  CAS  Google Scholar 

  35. Yilmaz M, Bukan N, Ersoy R, Karakoc A, Yetkin I, Ayvaz G et al. Glucose intolerance, insulin resistance and cardiovascular risk factors in first degree relatives of women with polycystic ovary syndrome. Hum Reprod 2005; 20(9):2414–2420.

    Article  PubMed  CAS  Google Scholar 

  36. Legro RS, Bentley-Lewis R, Driscoll D, Wang SC, Dunaif A. Insulin resistance in the sisters of women with polycystic ovary syndrome: association with hyperandrogenemia rather than menstrual irregularity. J Clin Endocrinol Metab 2002; 87(5):2128–2133.

    Article  PubMed  CAS  Google Scholar 

  37. Yildiz BO, Yarali H, Oguz H, Bayraktar M. Glucose intolerance, insulin resistance, and hyperandrogenemia in first degree relatives of women with polycystic ovary syndrome. J Clin Endocrinol Metab 2003; 88(5):2031–2036.

    Article  PubMed  CAS  Google Scholar 

  38. Norman RJ, Masters S, Hague W. Hyperinsulinemia is common in family members of women with polycystic ovary syndrome. Fertil Steril 1996; 66(6):942–947.

    PubMed  CAS  Google Scholar 

  39. Baillargeon JP, Carpentier AC. Brothers of women with polycystic ovary syndrome are characterised by impaired glucose tolerance, reduced insulin sensitivity and related metabolic defects. Diabetologia 2007; 50(12):2424–2432.

    Article  PubMed  Google Scholar 

  40. Koivunen RM, Morin-Papunen LC, Ruokonen A, Tapanainen JS, Martikainen HK. Ovarian steroidogenic response to human chorionic gonadotrophin in obese women with polycystic ovary syndrome: effect of metformin. Hum Reprod 2001; 16(12):2546–2551.

    Article  PubMed  CAS  Google Scholar 

  41. la Marca A, Egbe TO, Morgante G, Paglia T, Cianci A, De Leo V et al. Metformin treatment reduces ovarian cytochrome P-450c17alpha response to human chorionic gonadotrophin in women with insulin resistance-related polycystic ovary syndrome. Hum Reprod 2000; 15(1):21–23.

    Article  PubMed  Google Scholar 

  42. Jakubowicz DJ, Nestler JE. 17 alpha-Hydroxyprogesterone responses to leuprolide and serum androgens in obese women with and without polycystic ovary syndrome offer dietary weight loss. J Clin Endocrinol Metab 1997; 82(2):556–560.

    Article  PubMed  CAS  Google Scholar 

  43. Nestler JE, Jakubowicz DJ. Lean women with polycystic ovary syndrome respond to insulin reduction with decreases in ovarian P450c17 alpha activity and serum androgens. J Clin Endocrinol Metab 1997; 82(12):4075–4079.

    Article  PubMed  CAS  Google Scholar 

  44. Nestler JE, Jakubowicz DJ. Decreases in ovarian cytochrome P450c17 alpha activity and serum free testosterone after reduction of insulin secretion in polycystic ovary syndrome. N Engl J Med 1996; 335(9):617–623.

    Article  PubMed  CAS  Google Scholar 

  45. Ehrmann DA, Schneider DJ, Sobel BE, Cavaghan MK, Imperial J, Rosenfield RL et al. Troglitazone improves defects in insulin action, insulin secretion, ovarian steroidogenesis, and fibrinolysis in women with polycystic ovary syndrome. J Clin Endocrinol Metab 1997; 82(7):2108–2116.

    Article  PubMed  CAS  Google Scholar 

  46. Arslanian SA, Lewy V, Danadian K, Saad R. Metformin therapy in obese adolescents with polycystic ovary syndrome and impaired glucose tolerance: amelioration of exaggerated adrenal response to adrenocorticotropin with reduction of insulinemia/insulin resistance. J Clin Endocrinol Metab 2002; 87(4):1555–1559.

    Article  PubMed  CAS  Google Scholar 

  47. Vrbikova J, Hill M, Starka L, Cibula D, Bendlova B, Vondra K et al. The effects of long-term metformin treatment on adrenal and ovarian steroidogenesis in women with polycystic ovary syndrome. Eur J Endocrinol 2001; 144(6):619–628.

    Article  PubMed  CAS  Google Scholar 

  48. la Marca A, Morgante G, Paglia T, Ciotta L, Cianci A, De Leo V. Effects of metformin on adrenal steroidogenesis in women with polycystic ovary syndrome. [erratum appears in Fertil Steril 2000 Apr;73(4):874]. Fertil Steril 1999; 72(6): 985–989.

    Article  PubMed  Google Scholar 

  49. Romualdi D, Giuliani M, Draisci G, Costantini B, Cristello F, Lanzone A et al. Pioglitazone reduces the adrenal androgen response to corticotropin-releasing factor without changes in ACTH release in hyperinsulinemic women with polycystic ovary syndrome. Fertil Steril 2007; 88(1):131–138.

    Article  PubMed  CAS  Google Scholar 

  50. Guido M, Romualdi D, Suriano R, Giuliani M, Costantini B, Apa R et al. Effect of pioglitazone treatment on the adrenal androgen response to corticotrophin in obese patients with polycystic ovary syndrome. Hum Reprod 2004; 19(3):534–539.

    Article  PubMed  CAS  Google Scholar 

  51. Azziz R, Ehrmann DA, Legro RS, Fereshetian AG, O'Keefe M, Ghazzi MN. Troglitazone decreases adrenal androgen levels in women with polycystic ovary syndrome. Fertil Steril 2003; 79(4):932–937.

    Article  PubMed  Google Scholar 

  52. Nestler JE, Barlascini CO, Matt DW, Steingold KA, Plymate SR, Clore JN et al. Suppression of serum insulin by diazoxide reduces serum testosterone levels in obese women with polycystic ovary syndrome. J Clin Endocrinol Metab 1989; 68(6):1027–1032.

    Article  PubMed  CAS  Google Scholar 

  53. Penna IA, Canella PR, Reis RM, Silva de Sa MF, Ferriani RA. Acarbose in obese patients with polycystic ovarian syndrome: a double-blind, randomized, placebo-controlled study. Hum Reprod 2005; 20(9):2396–2401.

    Article  PubMed  CAS  Google Scholar 

  54. Ciotta L, Calogero AE, Farina M, De Leo V, la Marca A, Cianci A. Clinical, endocrine and metabolic effects of acarbose, an alpha-glucosidase inhibitor, in PCOS patients with increased insulin response and normal glucose tolerance. Hum Reprod 2001; 16(10):2066–2072.

    Article  PubMed  CAS  Google Scholar 

  55. Morin-Papunen LC, Vauhkonen I, Koivunen RM, Ruokonen A, Tapanainen JS. Insulin sensitivity, insulin secretion, and metabolic and hormonal parameters in healthy women and women with polycystic ovarian syndrome. Hum Reprod 2000; 15(6):1266–1274.

    Article  PubMed  CAS  Google Scholar 

  56. VrbIkova J, Cibula D, Dvorakova K, Stanicka S, Sindelka G, Hill M et al. Insulin Sensitivity in Women with Polycystic Ovary Syndrome. J Clin Endocrinol Metab 2004; 89(6):2942–2945.

    Article  PubMed  CAS  Google Scholar 

  57. Ciampelli M, Fulghesu AM, Cucinelli F, Pavone V, Caruso A, Mancuso S et al. Heterogeneity in beta cell activity, hepatic insulin clearance and peripheral insulin sensitivity in women with polycystic ovary syndrome. Hum Reprod 1997; 12(9):1897–1901.

    Article  PubMed  CAS  Google Scholar 

  58. Baillargeon JP, Jakubowicz DJ, Iuorno MJ, Jakubowicz S, Nestler JE. Effects of metformin and rosiglitazone, alone and in combination, in lean women with polycystic ovary syndrome and normal indices of insulin sensitivity. Fertil Steril 2004; 82(4):893–902.

    Article  PubMed  CAS  Google Scholar 

  59. Frias JP, Yu JG, Kruszynska YT, Olefsky JM. Metabolic effects of troglitazone therapy in type 2 diabetic, obese, and lean normal subjects. Diabetes Care 2000; 23(1):64–69.

    Article  PubMed  CAS  Google Scholar 

  60. Kruszynska YT, Yu JG, Olefsky JM, Sobel BE. Effects of troglitazone on blood concentrations of plasminogen activator inhibitor 1 in patients with type 2 diabetes and in lean and obese normal subjects. Diabetes 2000; 49(4):633–639.

    Article  PubMed  CAS  Google Scholar 

  61. Baillargeon JP, Carpentier A. Role of insulin in the hyperandrogenemia of lean women with polycystic ovary syndrome and normal insulin sensitivity. Fertil Steril 2007; 88(4):886–893.

    Article  PubMed  CAS  Google Scholar 

  62. Nestler JE, Singh R, Matt DW, Clore JN, Blackard WG. Suppression of serum insulin level by diazoxide does not alter serum testosterone or sex hormone-binding globulin levels in healthy, nonobese women. Am J Obstet Gynecol 1990; 163(4 Pt 1):1243–1246.

    PubMed  CAS  Google Scholar 

  63. Saltiel AR, Kahn CR. Insulin signalling and the regulation of glucose and lipid metabolism. Nature 2001; 414(6865): 799–806.

    Article  PubMed  CAS  Google Scholar 

  64. Wu XK, Zhou SY, Liu JX, Pollanen P, Sallinen K, Makinen M et al. Selective ovary resistance to insulin signaling in women with polycystic ovary syndrome. Fertil Steril 2003; 80(4):954–965.

    Article  PubMed  Google Scholar 

  65. Qu J, Wang Y, Wu X, Gao L, Hou L, Erkkola R. Insulin resistance directly contributes to androgenic potential within ovarian thecal cells. Fertil Steril 2008 Jul 29. [Epub ahead of print]; doi:10.1016/j.fertnstert.2008.02.167.

    Google Scholar 

  66. Baillargeon JP, Nestler JE. Polycystic ovary syndrome: A syndrome of ovarian hypersensitivity to insulin? J Clin Endocrinol Metab 2006; 91(1):22–24.

    Article  PubMed  CAS  Google Scholar 

  67. Yildiz BO, Knochenhauer ES, Azziz R. Impact of obesity on the risk for polycystic ovary syndrome. J Clin Endocrinol Metab 2008; 93(1):162–168.

    Article  PubMed  CAS  Google Scholar 

  68. Rebuffe-Scrive M, Cullberg G, Lundberg PA, Lindstedt G, Bjorntorp P. Anthropometric variables and metabolism in polycystic ovarian disease. Horm Metab Res 1989; 21(7):391–397.

    Article  PubMed  CAS  Google Scholar 

  69. Yildirim B, Sabir N, Kaleli B. Relation of intra-abdominal fat distribution to metabolic disorders in nonobese patients with polycystic ovary syndrome. Fertil Steril 2003; 79(6):1358–1364.

    Article  PubMed  Google Scholar 

  70. Barber TM, Golding SJ, Alvey C, Wass JA, Karpe F, Franks S et al. Global adiposity rather than abnormal regional fat distribution characterizes women with polycystic ovary syndrome. J Clin Endocrinol Metab 2008; 93(3):999–1004.

    Article  PubMed  CAS  Google Scholar 

  71. Michelmore K, Ong K, Mason S, Bennett S, Perry L, Vessey M et al. Clinical features in women with polycystic ovaries: relationships to insulin sensitivity, insulin gene VNTR and birth weight. Clin Endocrinol (Oxf) 2001; 55(4):439–446.

    Article  CAS  Google Scholar 

  72. Huber-Buchholz MM, Carey DGP, Norman RJ. Restoration of Reproductive potential by lifestyle modification in obese polycystic ovary syndrome: Role of insulin sensitivity and luteinizing hormone. J Clin Endocrinol Metab 1999; 84(4): 1470–1474.

    Article  PubMed  CAS  Google Scholar 

  73. Hoeger KM. Role of lifestyle modification in the management of polycystic ovary syndrome. Best Pract Res Clin Endocrinol Metab 2006; 20(2):293–310.

    Article  PubMed  Google Scholar 

  74. Despres JP, Lemieux I, Prud'homme D. Treatment of obesity: Need to focus on high risk abdominally obese patients. BMJ 2001; 322(7288):716–720.

    Article  PubMed  CAS  Google Scholar 

  75. Diamanti-Kandarakis E, Katsikis I, Piperi C, Alexandraki K, Panidis D. Effect of long-term orlistat treatment on serum levels of advanced glycation end-products in women with polycystic ovary syndrome. Clin Endocrinol (Oxf) 2007; 66(1):103–109.

    CAS  Google Scholar 

  76. Panidis D, Farmakiotis D, Rousso D, Kourtis A, Katsikis I, Krassas G. Obesity, weight loss, and the polycystic ovary syndrome: effect of treatment with diet and orlistat for 24 weeks on insulin resistance and androgen levels. Fertil Steril 2008; 89(4):899–906.

    Article  PubMed  Google Scholar 

  77. Lindholm A, Bixo M, Bjorn I, Wolner-Hanssen P, Eliasson M, Larsson A et al. Effect of sibutramine on weight reduction in women with polycystic ovary syndrome: a randomized, double-blind, placebo-controlled trial. Fertil Steril 2008; 89(5): 1221–1228.

    Article  PubMed  CAS  Google Scholar 

  78. Sathyapalan T, Cho L, Kilpatrick ES, Coady AM, Atkin SL. A comparison between rimonabant and metformin in reducing biochemical hyperandrogenaemia and insulin resistance in patients with polycystic ovary syndrome: a randomised open labelled parallel study. Clin Endocrinol (Oxf) 2008; [Epub ahead of print].

    Google Scholar 

  79. Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002; 346(6):393–403.

    Article  PubMed  CAS  Google Scholar 

  80. Tuomilehto J, Lindstrom J, Eriksson JG, Valle TT, Hamalainen H, Ilanne-Parikka P et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 2001; 344(18):1343–1350.

    Article  PubMed  CAS  Google Scholar 

  81. Ramachandran A, Snehalatha C, Mary S, Mukesh B, Bhaskar AD, Vijay V. The Indian Diabetes Prevention Programme shows that lifestyle modification and metformin prevent type 2 diabetes in Asian Indian subjects with impaired glucose tolerance (IDPP-1). Diabetologia 2006; 49(2):289–297.

    Article  PubMed  CAS  Google Scholar 

  82. Pan XR, Li GW, Hu YH, Wang JX, Yang WY, An ZX et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. The Da Qing IGT and Diabetes Study. Diabetes Care 1997; 20(4):537–544.

    Article  PubMed  CAS  Google Scholar 

  83. Torgerson JS, Hauptman J, Boldrin MN, Sjostrom L. XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care 2004; 27(1):155–161.

    Article  PubMed  CAS  Google Scholar 

  84. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril 2004; 81(1):19–25.

    Article  Google Scholar 

  85. Baillargeon JP, Iuorno MJ, Nestler JE. Insulin sensitizers for polycystic ovary syndrome. Clin Obstet Gynecol 2003; 46(2):325–340.

    Article  PubMed  Google Scholar 

  86. Rimm EB, Manson JE, Stampfer MJ, Colditz GA, Willett WC, Rosner B et al. Oral contraceptive use and the risk of type 2 (non-insulin-dependent) diabetes mellitus in a large prospective study of women. Diabetologia 1992; 35(10):967–972.

    Article  PubMed  CAS  Google Scholar 

  87. Chasan-Taber L, Willett WC, Stampfer MJ, Hunter DJ, Colditz GA, Spiegelman D et al. A prospective study of oral contraceptives and NIDDM among U.S. women. Diabetes Care 1997; 20(3):330–335.

    Article  PubMed  CAS  Google Scholar 

  88. Baillargeon JP, McClish DK, Essah PA, Nestler JE. Association between the current use of low-dose oral contraceptives and cardiovascular arterial disease: A meta-analysis. J Clin Endocrinol Metab 2005; 90(7):3863–3870.

    Article  PubMed  CAS  Google Scholar 

  89. Beral V, Hermon C, Kay C, Hannaford P, Darby S, Reeves G. Mortality associated with oral contraceptive use: 25 year follow up of cohort of 46 000 women from Royal College of General Practitioners' oral contraception study. BMJ 1999; 318(7176):96–100.

    Article  PubMed  CAS  Google Scholar 

  90. Stampfer MJ, Willett WC, Colditz GA, Speizer FE, Hennekens CH. A prospective study of past use of oral contraceptive agents and risk of cardiovascular diseases. N Engl J Med 1988; 319(20):1313–1317.

    Article  PubMed  CAS  Google Scholar 

  91. Shaw RJ, Lamia KA, Vasquez D, Koo SH, Bardeesy N, Depinho RA et al. The kinase LKB1 mediates glucose homeostasis in liver and therapeutic effects of metformin. Science 2005; 310(5754):1642–1646.

    Article  PubMed  CAS  Google Scholar 

  92. Creanga AA, Bradley HM, McCormick C, Witkop CT. Use of metformin in polycystic ovary syndrome: a meta-analysis. Obstet Gynecol 2008; 111(4):959–968.

    Article  PubMed  CAS  Google Scholar 

  93. Bruno RV, de Avila MA, Neves FB, Nardi AE, Crespo CM, Sobrinho AT. Comparison of two doses of metformin (2.5 and 1.5 g/day) for the treatment of polycystic ovary syndrome and their effect on body mass index and waist circumference. Fertil Steril 2007; 88(2):510–512.

    Article  PubMed  CAS  Google Scholar 

  94. Maciel GA, Soares Junior JM, Alves da Motta EL, Abi HM, de Lima GR, Baracat EC. Nonobese women with polycystic ovary syndrome respond better than obese women to treatment with metformin. Fertil Steril 2004; 81(2):355–360.

    Article  PubMed  CAS  Google Scholar 

  95. Palomba S, Falbo A, Orio F, Jr., Tolino A, Zullo F. Efficacy predictors for metformin and clomiphene citrate treatment in anovulatory infertile patients with polycystic ovary syndrome. Fertil Steril 2008; [Epub ahead of print].

    Google Scholar 

  96. Garber AJ, Duncan TG, Goodman AM, Mills DJ, Rohlf JL. Efficacy of metformin in type II diabetes: results of a double-blind, placebo-controlled, dose-response trial. Am J Med 1997; 103(6):491–497.

    Article  PubMed  CAS  Google Scholar 

  97. Lord JM, Flight IH, Norman RJ. Metformin in polycystic ovary syndrome: systematic review and meta-analysis. BMJ 2003; 327(7421):951–953.

    Article  PubMed  CAS  Google Scholar 

  98. Moll E, Bossuyt PM, Korevaar JC, Lambalk CB, van der Veen, F. Effect of clomifene citrate plus metformin and clomifene citrate plus placebo on induction of ovulation in women with newly diagnosed polycystic ovary syndrome: randomised double blind clinical trial. BMJ 2006; 332(7556):1485.

    Article  PubMed  CAS  Google Scholar 

  99. Schwartz S, Fonseca V, Berner B, Cramer M, Chiang YK, Lewin A. Efficacy, tolerability, and safety of a novel once-daily extended-release metformin in patients with type 2 diabetes. Diabetes Care 2006; 29(4):759–764.

    Article  PubMed  CAS  Google Scholar 

  100. Legro RS, Barnhart HX, Schlaff WD, Carr BR, Diamond MP, Carson SA et al. Clomiphene, metformin, or both for infertility in the polycystic ovary syndrome. N Engl J Med 2007; 356(6):551–566.

    Article  PubMed  CAS  Google Scholar 

  101. Desilets AR, Dhakal-Karki S, Dunican KC. Role of metformin for weight management in patients without type 2 diabetes. Ann Pharmacother 2008; 42(6):817–826.

    Article  PubMed  CAS  Google Scholar 

  102. Rowan JA, Hague WM, Gao W, Battin MR, Moore MP. Metformin versus insulin for the treatment of gestational diabetes. N Engl J Med 2008; 358(19):2003–2015.

    Article  PubMed  CAS  Google Scholar 

  103. Bolton S, Cleary B, Walsh J, Dempsey E, Turner MJ. Continuation of metformin in the first trimester of women with polycystic ovarian syndrome is not associated with increased perinatal morbidity. Eur J Pediatr 2008; [Epub ahead of print].

    Google Scholar 

  104. Moore LE, Briery CM, Clokey D, Martin RW, Williford NJ, Bofill JA et al. Metformin and insulin in the management of gestational diabetes mellitus: preliminary results of a comparison. J Reprod Med 2007; 52(11):1011–1015.

    PubMed  CAS  Google Scholar 

  105. Gilbert C, Valois M, Koren G. Pregnancy outcome after first-trimester exposure to metformin: A meta-analysis. Fertil Steril 2006; 86(3):658–663.

    Article  PubMed  CAS  Google Scholar 

  106. Glueck CJ, Goldenberg N, Pranikoff J, Loftspring M, Sieve L, Wang P. Height, weight, and motor-social development during the first 18 months of life in 126 infants born to 109 mothers with polycystic ovary syndrome who conceived on and continued metformin through pregnancy. Hum Reprod 2004; 19(6):1323–1330.

    Article  PubMed  CAS  Google Scholar 

  107. Vanky E, Salvesen KA, Heimstad R, Fougner KJ, Romundstad P, Carlsen SM. Metformin reduces pregnancy complications without affecting androgen levels in pregnant polycystic ovary syndrome women: results of a randomized study. Hum Reprod 2004; 19(8):1734–1740.

    Article  PubMed  CAS  Google Scholar 

  108. Gutzin SJ, Kozer E, Magee LA, Feig DS, Koren G. The safety of oral hypoglycemic agents in the first trimester of pregnancy: A meta-analysis. Can J Clin Pharmacol 2003; 10(4):179–183.

    PubMed  Google Scholar 

  109. Coetzee EJ, Jackson WP. The management of non-insulin-dependent diabetes during pregnancy. Diabetes Res Clin Pract – Suppl 1985; 1(5):281–287.

    Article  Google Scholar 

  110. Hellmuth E, Damm P, Molsted-Pedersen L. Oral hypoglycaemic agents in 118 diabetic pregnancies. Diabetic Medicine 2000; 17(7):507–511.

    Article  PubMed  CAS  Google Scholar 

  111. Karalliedde J, Buckingham RE. Thiazolidinediones and their fluid-related adverse effects: facts, fiction and putative management strategies. Drug Saf 2007; 30(9):741–753.

    Article  PubMed  CAS  Google Scholar 

  112. Hermansen K, Mortensen LS. Bodyweight changes associated with antihyperglycaemic agents in type 2 diabetes mellitus. Drug Saf 2007; 30(12):1127–1142.

    Article  PubMed  CAS  Google Scholar 

  113. Kahn SE, Haffner SM, Heise MA, Herman WH, Holman RR, Jones NP et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 2006; 355(23):2427–2443.

    Article  PubMed  CAS  Google Scholar 

  114. Glintborg D, Andersen M, Hagen C, Heickendorff L, Hermann AP. Association of pioglitazone treatment with decreased bone mineral density in obese premenopausal patients with polycystic ovary syndrome: a randomized, placebo-controlled trial. J Clin Endocrinol Metab 2008; 93(5):1696–1701.

    Article  PubMed  CAS  Google Scholar 

  115. Demissie YN, Fiad TM, Klemm K, Twfeeg A, Al Amoudi A, Meer L et al. Spontaneous singleton and twin pregnancy in two patients with polycystic ovary syndrome and type 2 diabetes following treatment with metformin combined with rosiglitazone. Ann Saudi Med 2006; 26(4):296–299.

    PubMed  Google Scholar 

  116. Choi JS, Han JY, Ahn HK, Shin JS, Yang JH, Koong MK et al. Exposure to rosiglitazone and fluoxetine in the first trimester of pregnancy. Diabetes Care 2006; 29(9):2176.

    Article  PubMed  Google Scholar 

  117. Ortega-Gonzalez C, Luna S, Hernandez L, Crespo G, Aguayo P, Arteaga-Troncoso G et al. Responses of Serum Androgen and Insulin Resistance to Metformin and Pioglitazone in Obese, Insulin-Resistant Women with Polycystic Ovary Syndrome. J Clin Endocrinol Metab 2005; 90(3):1360–1365.

    Article  PubMed  CAS  Google Scholar 

  118. Kalyoncu NI, Yaris F, Ulku C, Kadioglu M, Kesim M, Unsal M et al. A case of rosiglitazone exposure in the second trimester of pregnancy. Reprod Toxicol 2005; 19(4):563–564.

    Article  PubMed  CAS  Google Scholar 

  119. Yaris F, Yaris E, Kadioglu M, Ulku C, Kesim M, Kalyoncu NI. Normal pregnancy outcome following inadvertent exposure to rosiglitazone, gliclazide, and atorvastatin in a diabetic and hypertensive woman. Reprod Toxicol 2004; 18(4):619–621.

    Article  PubMed  CAS  Google Scholar 

  120. Ghazeeri G, Kutteh WH, Bryer-Ash M, Haas D, Ke RW. Effect of rosiglitazone on spontaneous and clomiphene citrate-induced ovulation in women with polycystic ovary syndrome. Fertil Steril 2003; 79(3):562–566.

    Article  PubMed  Google Scholar 

  121. Kashyap S, Wells GA, Rosenwaks Z. Insulin-sensitizing agents as primary therapy for patients with polycystic ovarian syndrome. Hum Reprod 2004; 19(11):2474–2483.

    Article  PubMed  CAS  Google Scholar 

  122. Palomba S, Orio F, Jr, Falbo A, Manguso F, Russo T, Cascella T et al. Prospective parallel randomized, double-blind, double-dummy controlled clinical trial comparing clomiphene citrate and metformin as the first-line treatment for ovulation induction in nonobese anovulatory women with polycystic ovary syndrome. J Clin Endocrinol Metab 2005; 90(7):4068–4074.

    Article  PubMed  CAS  Google Scholar 

  123. Palomba S, Orio F, Jr, Falbo A, Russo T, Tolino A, Zullo F. Clomiphene citrate versus metformin as first-line approach for the treatment of anovulation in infertile patients with polycystic ovary syndrome. J Clin Endocrinol Metab 2007; 92(9): 3498–3503.

    Article  PubMed  CAS  Google Scholar 

  124. Neveu N, Granger L, St Michel P, Lavoie HB. Comparison of clomiphene citrate, metformin, or the combination of both for first-line ovulation induction and achievement of pregnancy in 154 women with polycystic ovary syndrome. Fertil Steril 2007; 87(1):113–120.

    Article  PubMed  CAS  Google Scholar 

  125. Legro RS, Barnhart HX, Schlaff WD, Carr BR, Diamond MP, Carson SA et al. Ovulatory response to treatment of polycystic ovary syndrome is associated with a polymorphism in the STK11 gene. J Clin Endocrinol Metab 2008; 93(3):792–800.

    Article  PubMed  CAS  Google Scholar 

  126. Khattab S, Mohsen IA, Foutouh IA, Ramadan A, Moaz M, Al Inany H. Metformin reduces abortion in pregnant women with polycystic ovary syndrome. Gynecol Endocrinol 2006; 22(12):680–684.

    Article  PubMed  CAS  Google Scholar 

  127. Jakubowicz DJ, Iuorno MJ, Jakubowicz S, Roberts KA, Nestler JE. Effects of metformin on early pregnancy loss in the polycystic ovary syndrome. J Clin Endocrinol Metab 2002; 87(2):524–529.

    Article  PubMed  CAS  Google Scholar 

  128. Glueck CJ, Wang P, Goldenberg N, Sieve-Smith L. Pregnancy outcomes among women with polycystic ovary syndrome treated with metformin. Hum Reprod 2002; 17(11):2858–2864.

    Article  PubMed  CAS  Google Scholar 

  129. Palomba S, Orio F, Jr, Nardo LG, Falbo A, Russo T, Corea D et al. Metformin administration versus laparoscopic ovarian diathermy in clomiphene citrate-resistant women with polycystic ovary syndrome: A prospective parallel randomized double-blind placebo-controlled trial. J Clin Endocrinol Metab 2004; 89(10):4801–4809.

    Article  PubMed  CAS  Google Scholar 

  130. Balen AH, Tan SL, MacDougall J, Jacobs HS. Miscarriage rates following in-vitro fertilization are increased in women with polycystic ovaries and reduced by pituitary desensitization with buserelin. Hum Reprod 1993; 8(6):959–964.

    PubMed  CAS  Google Scholar 

  131. Sagle M, Bishop K, Ridley N, Alexander FM, Michel M, Bonney RC et al. Recurrent early miscarriage and polycystic ovaries. BMJ 1988; 297(6655):1027–1028.

    Article  PubMed  CAS  Google Scholar 

  132. Jakubowicz DJ, Essah PA, Seppala M, Jakubowicz S, Baillargeon J-P, Koistinen R et al. Reduced serum glycodelin and insulin-like growth factor-binding protein-1 in women with polycystic ovary syndrome during first trimester of pregnancy. J Clin Endocrinol Metab 2004; 89(2):833–839.

    Article  PubMed  CAS  Google Scholar 

  133. Jakubowicz DJ, Seppala M, Jakubowicz S, Rodriguez-Armas O, Rivas-Santiago A, Koistinen H et al. Insulin reduction with metformin increases luteal phase serum glycodelin and insulin-like growth factor-binding protein 1 concentrations and enhances uterine vascularity and blood flow in the polycystic ovary syndrome. J Clin Endocrinol Metab 2001; 86(3): 1126–1133.

    Article  PubMed  CAS  Google Scholar 

  134. Ratts VS, Pauls RN, Pinto AB, Kraja A, Williams DB, Odem RR. Risk of multiple gestation after ovulation induction in polycystic ovary syndrome. J Reprod Med 2007; 52(10):896–900.

    PubMed  Google Scholar 

  135. Azziz R, Ehrmann D, Legro RS, Whitcomb RW, Hanley R, Fereshetian AG et al. Troglitazone improves ovulation and hirsutism in the polycystic ovary syndrome: a multicenter, double blind, placebo-controlled trial. J Clin Endocrinol Metab 2001; 86(4):1626–1632.

    Article  PubMed  CAS  Google Scholar 

  136. Rautio K, Tapanainen JS, Ruokonen A, Morin-Papunen LC. Endocrine and metabolic effects of rosiglitazone in overweight women with PCOS: a randomized placebo-controlled study. Human reproduction (Oxford, England) 2006.

    Google Scholar 

  137. Brettenthaler N, De Geyter C, Huber PR, Keller U. Effect of the insulin sensitizer pioglitazone on insulin resistance, hyperandrogenism, and ovulatory dysfunction in women with polycystic ovary syndrome. J Clin Endocrinol Metab 2004; 89(8): 3835–3840.

    Article  PubMed  CAS  Google Scholar 

  138. Mitwally MF, Kuscu NK, Yalcinkaya TM. High ovulatory rates with use of troglitazone in clomiphene-resistant women with polycystic ovary syndrome. Hum Reprod 1999; 14(11):2700–2703.

    Article  PubMed  CAS  Google Scholar 

  139. Zhang CL, Gao HY, Zhao ZG, Jia P. Effect of rosiglitazone on ovulation induction in women with polycystic ovary syndrome. Chung Hua Fu Chan Ko Tsa Chih 2004; 39(3):173–175.

    PubMed  CAS  Google Scholar 

  140. Shobokshi A, Shaarawy M. Correction of insulin resistance and hyperandrogenism in polycystic ovary syndrome by combined rosiglitazone and clomiphene citrate therapy. Journal of the Society for Gynecologic Investigation 2003; 10(2): 99–104.

    Article  PubMed  CAS  Google Scholar 

  141. Rouzi AA, Ardawi MS. A randomized controlled trial of the efficacy of rosiglitazone and clomiphene citrate versus metformin and clomiphene citrate in women with clomiphene citrate-resistant polycystic ovary syndrome. Fertil Steril 2006; 85(2): 428–435.

    Article  PubMed  CAS  Google Scholar 

  142. Kelly CJ, Gordon D. The effect of metformin on hirsutism in polycystic ovary syndrome. Eur J Endocrinol 2002; 147(2): 217–221.

    Article  PubMed  CAS  Google Scholar 

  143. Harborne L, Fleming R, Lyall H, Sattar N, Norman J. Metformin or Antiandrogen in the treatment of hirsutism in polycystic ovary syndrome. J Clin Endocrinol Metab 2003; 88(9):4116–4123.

    Article  PubMed  CAS  Google Scholar 

  144. Kolodziejczyk B, Duleba AJ, Spaczynski RZ, Pawelczyk L. Metformin therapy decreases hyperandrogenism and hyperinsulinemia in women with polycystic ovary syndrome. Fertil Steril 2000; 73(6):1149–1154.

    Article  PubMed  CAS  Google Scholar 

  145. Ibanez L, Valls C, Ferrer A, Marcos MV, Rodriguez-Hierro F, de Zegher F. Sensitization to insulin induces ovulation in nonobese adolescents with anovulatory hyperandrogenism. J Clin Endocrinol Metab 2001; 86(8):3595–3598.

    Article  PubMed  CAS  Google Scholar 

  146. Loverro G, Lorusso F, De Pergola G, Nicolardi V, Mei L, Selvaggi L. Clinical and endocrinological effects of 6 months of metformin treatment in young hyperinsulinemic patients affected by polycystic ovary syndrome. Gynecol Endocrinol 2002; 16(3):217–224.

    PubMed  CAS  Google Scholar 

  147. Kazerooni T, Dehghan-Kooshkghazi M. Effects of metformin therapy on hyperandrogenism in women with polycystic ovarian syndrome. Gynecol Endocrinol 2003; 17(1):51–56.

    PubMed  CAS  Google Scholar 

  148. Aruna J, Mittal S, Kumar S, Misra R, Dadhwal V, Vimala N. Metformin therapy in women with polycystic ovary syndrome. Int J Gynaecol Obstet 2004; 87(3):237–241.

    Article  PubMed  CAS  Google Scholar 

  149. Kriplani A, Agarwal N. Effects of metformin on clinical and biochemical parameters in polycystic ovary syndrome. J Reprod Med 2004; 49(5):361–367.

    PubMed  CAS  Google Scholar 

  150. Marcondes JA, Yamashita SA, Maciel GA, Baracat EC, Halpern A. Metformin in normal-weight hirsute women with polycystic ovary syndrome with normal insulin sensitivity. Gynecol Endocrinol 2007; 23(5):273–278.

    Article  PubMed  CAS  Google Scholar 

  151. Cicek MN, Bala A, Celik C, Akyurek C. The comparison of clinical and hormonal parameters in PCOS patients treated with metformin and GnRH analogue. Archives of Gynecology & Obstetrics 2003; 268(2):107–112.

    CAS  Google Scholar 

  152. Gambineri A, Pelusi C, Genghini S, Morselli-Labate AM, Cacciari M, Pagotto U et al. Effect of flutamide and metformin administered alone or in combination in dieting obese women with polycystic ovary syndrome. Clin Endocrinol (Oxf) 2004; 60(2):241–249.

    Article  CAS  Google Scholar 

  153. Ganie MA, Khurana ML, Eunice M, Gulati M, Dwivedi SN, Ammini AC. Comparison of efficacy of spironolactone with metformin in the management of polycystic ovary syndrome: An open-labeled study. J Clin Endocrinol Metab 2004; 89(6): 2756–2762.

    Article  PubMed  CAS  Google Scholar 

  154. Yilmaz M, Karakoc A, Toruner FB, Cakir N, Tiras B, Ayvaz G et al. The effects of rosiglitazone and metformin on menstrual cyclicity and hirsutism in polycystic ovary syndrome. Gynecol Endocrinol 2005; 21(3):154–160.

    Article  PubMed  CAS  Google Scholar 

  155. Meyer C, McGrath BP, Teede HJ. Effects of medical therapy on insulin resistance and the cardiovascular system in polycystic ovary syndrome. Diabetes Care 2007; 30(3):471–478.

    Article  PubMed  CAS  Google Scholar 

  156. Orio F, Jr, Palomba S, Cascella T, De Simone B, Manguso F, Savastano S et al. Improvement in endothelial structure and function after metformin treatment in young normal-weight women with polycystic ovary syndrome: Results of a 6-month study. J Clin Endocrinol Metab 2005; 90(11):6072–6076.

    Article  PubMed  CAS  Google Scholar 

  157. Morin-Papunen L, Vauhkonen I, Koivunen R, Ruokonen A, Martikainen H, Tapanainen JS. Metformin versus ethinyl estradiol-cyproterone acetate in the treatment of nonobese women with polycystic ovary syndrome: A randomized study. J Clin Endocrinol Metab 2003; 88(1):148–156.

    Article  PubMed  CAS  Google Scholar 

  158. Gambineri A, Patton L, Vaccina A, Cacciari M, Morselli-Labate AM, Cavazza C et al. Treatment with flutamide, metformin, and their combination added to a hypocaloric diet in overweight-obese women with polycystic ovary syndrome: A randomized, 12-month, placebo-controlled study. J Clin Endocrinol Metab 2006; 91(10):3970–3980.

    Article  PubMed  CAS  Google Scholar 

  159. Ibanez L, Valls C, Ferrer A, Ong K, Dunger DB, de Zegher F. Additive effects of insulin-sensitizing and anti-androgen treatment in young, nonobese women with hyperinsulinism, hyperandrogenism, dyslipidemia, and anovulation. J Clin Endocrinol Metab 2002; 87(6):2870–2874.

    Article  PubMed  CAS  Google Scholar 

  160. Romualdi D, Guido M, Ciampelli M, Giuliani M, Leoni F, Perri C et al. Selective effects of pioglitazone on insulin and androgen abnormalities in normo- and hyperinsulinaemic obese patients with polycystic ovary syndrome. Hum Reprod 2003; 18(6):1210–1218.

    Article  PubMed  CAS  Google Scholar 

  161. Dereli D, Dereli T, Bayraktar F, Ozgen AG, Yilmaz C. Endocrine and metabolic effects of rosiglitazone in non-obese women with polycystic ovary disease. Endocr J 2005; 52(3):299–308.

    Article  PubMed  CAS  Google Scholar 

  162. Tarkun I, Cetinarslan B, Turemen E, Sahin T, Canturk Z, Komsuoglu B. Effect of rosiglitazone on insulin resistance, C-reactive protein and endothelial function in non-obese young women with polycystic ovary syndrome. Eur J Endocrinol 2005; 153(1):115–121.

    Article  PubMed  CAS  Google Scholar 

  163. Lemay A, Dodin S, Turcot L, Dechene F, Forest JC. Rosiglitazone and ethinyl estradiol/cyproterone acetate as single and combined treatment of overweight women with polycystic ovary syndrome and insulin resistance. Hum Reprod 2006; 21(1): 121–128.

    Article  PubMed  CAS  Google Scholar 

  164. Sharma ST, Wickham EP, III, Nestler JE. Changes in glucose tolerance with metformin treatment in polycystic ovary syndrome: a retrospective analysis. Endocr Pract 2007; 13(4):373–379.

    Google Scholar 

  165. Luque-Ramirez M, Alvarez-Blasco F, Botella-Carretero JI, Martinez-Bermejo E, Lasuncion MA, Escobar-Morreale HF. Comparison of ethinyl-estradiol plus cyproterone acetate versus metformin effects on classic metabolic cardiovascular risk factors in women with the polycystic ovary syndrome. J Clin Endocrinol Metab 2007; 92(7):2453–2461.

    Article  PubMed  CAS  Google Scholar 

  166. Romualdi D, Costantini B, Selvaggi L, Giuliani M, Cristello F, Macri F et al. Metformin improves endothelial function in normoinsulinemic PCOS patients: a new prospective. Hum Reprod 2008.

    Google Scholar 

  167. Topcu S, Tok D, Caliskan M, Ozcimen EE, Gullu H, Uckuyu A et al. Metformin therapy improves coronary microvascular function in patients with polycystic ovary syndrome and insulin resistance. Clin Endocrinol (Oxf) 2006; 65(1): 75–80.

    Article  CAS  Google Scholar 

  168. Luque-Ramirez M, Mendieta-Azcona C, Alvarez-Blasco F, Escobar-Morreale HF. Effects of metformin versus ethinyl-estradiol plus cyproterone acetate on ambulatory blood pressure monitoring and carotid intima media thickness in women with the polycystic ovary syndrome. Fertil Steril 2008.

    Google Scholar 

  169. Goldenberg N, Glueck CJ, Loftspring M, Sherman A, Wang P. Metformin-diet benefits in women with polycystic ovary syndrome in the bottom and top quintiles for insulin resistance. Metabolism 2005; 54(1):113–121.

    Article  PubMed  CAS  Google Scholar 

  170. Moghetti P, Castello R, Negri C, Tosi F, Perrone F, Caputo M et al. Metformin effects on clinical features, endocrine and metabolic profiles, and insulin sensitivity in polycystic ovary syndrome: a randomized, double-blind, placebo-controlled 6-month trial, followed by open, long-term clinical evaluation. J Clin Endocrinol Metab 2000; 85(1):139–146.

    Article  PubMed  CAS  Google Scholar 

  171. Fleming R, Hopkinson ZE, Wallace AM, Greer IA, Sattar N. Ovarian function and metabolic factors in women with oligomenorrhea treated with metformin in a randomized double blind placebo-controlled trial. J Clin Endocrinol Metab 2002; 87(2):569–574.

    Article  PubMed  CAS  Google Scholar 

  172. Morin-Papunen L, Rautio K, Ruokonen A, Hedberg P, Puukka M, Tapanainen JS. Metformin reduces serum C-reactive protein levels in women with polycystic ovary syndrome. J Clin Endocrinol Metab 2003; 88(10):4649–4654.

    Article  PubMed  CAS  Google Scholar 

  173. Diamanti-Kandarakis E, Spina G, Kouli C, Migdalis I. Increased endothelin-1 levels in women with polycystic ovary syndrome and the beneficial effect of metformin therapy. J Clin Endocrinol Metab 2001; 86(10):4666–4673.

    Article  PubMed  CAS  Google Scholar 

  174. Wu J, Zhu Y, Jiang Y, Cao Y. Effects of metformin and ethinyl estradiol-cyproterone acetate on clinical, endocrine and metabolic factors in women with polycystic ovary syndrome. Gynecol Endocrinol 2008; [Epub ahead of print]:1–7.

    Google Scholar 

  175. Ibanez L, de Zegher F. Ethinylestradiol-drospirenone, flutamide-metformin, or both for adolescents and women with hyperinsulinemic hyperandrogenism: opposite effects on adipocytokines and body adiposity. J Clin Endocrinol Metab 2004; 89(4):1592–1597.

    Article  PubMed  CAS  Google Scholar 

  176. Sahin Y, Unluhizarci K, Yilmazsoy A, Yikilmaz A, Aygen E, Kelestimur F. The effects of metformin on metabolic and cardiovascular risk factors in nonobese women with polycystic ovary syndrome. Clin Endocrinol (Oxf) 2007; 67(6): 904–908.

    Article  CAS  Google Scholar 

  177. Tan S, Hahn S, Benson S, Dietz T, Lahner H, Moeller LC et al. Metformin improves polycystic ovary syndrome symptoms irrespective of pre-treatment insulin resistance. Eur J Endocrinol 2007; 157(5):669–676.

    Article  PubMed  CAS  Google Scholar 

  178. Nawrocka J, Starczewski A. Effects of metformin treatment in women with polycystic ovary syndrome depends on insulin resistance. Gynecol Endocrinol 2007; 23(4):231–237.

    Article  PubMed  CAS  Google Scholar 

  179. Salley KE, Wickham EP, Cheang KI, Essah PA, Karjane NW, Nestler JE. Glucose intolerance in polycystic ovary syndrome--a position statement of the Androgen Excess Society. J Clin Endocrinol Metab 2007; 92(12):4546–4556.

    Article  PubMed  CAS  Google Scholar 

  180. Gagnon C, Baillargeon JP. Suitability of recommended limits for fasting glucose tests in women with polycystic ovary syndrome. CMAJ 2007; 176(7):933–938.

    Article  PubMed  Google Scholar 

  181. Glueck CJ, Moreira A, Goldenberg N, Sieve L, Wang P. Pioglitazone and metformin in obese women with polycystic ovary syndrome not optimally responsive to metformin. Hum Reprod 2003; 18(8):1618–1625.

    Article  PubMed  CAS  Google Scholar 

  182. Glueck CJ, Aregawi D, Agloria M, Winiarska M, Sieve L, Wang P. Sustainability of 8% weight loss, reduction of insulin resistance, and amelioration of atherogenic-metabolic risk factors over 4 years by metformin-diet in women with polycystic ovary syndrome. Metabolism 2006; 55(12):1582–1589.

    Article  PubMed  CAS  Google Scholar 

  183. Lo JC, Feigenbaum SL, Escobar GJ, Yang J, Crites YM, Ferrara A. Increased prevalence of gestational diabetes mellitus among women with diagnosed polycystic ovary syndrome: a population-based study. Diabetes Care 2006; 29(8):1915–1917.

    Article  PubMed  Google Scholar 

  184. Standards of medical care in diabetes--2006. Diabetes Care 2006; 29 Suppl 1:S4–S42.

    Google Scholar 

  185. Turner MJ, Walsh J, Byrne KM, Murphy C, Langan H, Farah N. Outcome of clinical pregnancies after ovulation induction using metformin. J Obstet Gynaecol 2006; 26(3):233–235.

    Article  PubMed  CAS  Google Scholar 

  186. Glueck CJ, Bornovali S, Pranikoff J, Goldenberg N, Dharashivkar S, Wang P. Metformin, pre-eclampsia, and pregnancy outcomes in women with polycystic ovary syndrome. Diabetic Med 2004; 21(8):829–836.

    Article  PubMed  CAS  Google Scholar 

  187. Glueck CJ, Pranikoff J, Aregawi D, Wang P. Prevention of gestational diabetes by metformin plus diet in patients with polycystic ovary syndrome. Fertil Steril 2008; 89(3):625–634.

    Article  PubMed  CAS  Google Scholar 

  188. Siega-Riz AM, Laraia B. The implications of maternal overweight and obesity on the course of pregnancy and birth outcomes. Matern Child Health J 2006; 10(5 Suppl):S153-S156.

    Article  PubMed  Google Scholar 

  189. Chu SY, Kim SY, Schmid CH, Dietz PM, Callaghan WM, Lau J et al. Maternal obesity and risk of cesarean delivery: a meta-analysis. Obes Rev 2007; 8(5):385–394.

    Article  PubMed  CAS  Google Scholar 

  190. Chu SY, Kim SY, Lau J, Schmid CH, Dietz PM, Callaghan WM et al. Maternal obesity and risk of stillbirth: a metaanalysis. Am J Obstet Gynecol 2007; 197(3):223–228.

    Article  PubMed  Google Scholar 

  191. Chu SY, Callaghan WM, Kim SY, Schmid CH, Lau J, England LJ et al. Maternal obesity and risk of gestational diabetes mellitus. Diabetes Care 2007; 30(8):2070–2076.

    Article  PubMed  Google Scholar 

  192. Chu SY, Bachman DJ, Callaghan WM, Whitlock EP, Dietz PM, Berg CJ et al. Association between obesity during pregnancy and increased use of health care. N Engl J Med 2008; 358(14):1444–1453.

    Article  PubMed  CAS  Google Scholar 

  193. Harlass FE, Plymate SR, Fariss BL, Belts RP. Weight loss is associated with correction of gonadotropin and sex steroid abnormalities in the obese anovulatory female. Fertil Steril 1984; 42(4):649–652.

    PubMed  CAS  Google Scholar 

  194. Pasquali R, Antenucci D, Casimirri F, Venturoli S, Paradisi R, Fabbri R et al. Clinical and hormonal characteristics of obese amenorrheic hyperandrogenic women before and after weight loss. J Clin Endocrinol Metab 1989; 68(1):173–179.

    Article  PubMed  CAS  Google Scholar 

  195. Kiddy DS, Hamilton-Fairley D, Bush A, Short F, Anyaoku V, Reed MJ et al. Improvement in endocrine and ovarian function during dietary treatment of obese women with polycystic ovary syndrome. Clin Endocrinol (Oxf) 1992; 36(1):105–111.

    Article  CAS  Google Scholar 

  196. Hamilton-Fairley D, Kiddy D, Anyaoku V, Koistinen R, Seppala M, Franks S. Response of sex hormone binding globulin and insulin-like growth factor binding protein-1 to an oral glucose tolerance test in obese women with polycystic ovary syndrome before and after calorie restriction. Clin Endocrinol (Oxf) 1993; 39(3):363–367.

    Article  CAS  Google Scholar 

  197. Guzick DS, Wing R, Smith D, Berga SL, Winters SJ. Endocrine consequences of weight loss in obese, hyperandrogenic, anovulatory women. Fertil Steril 1994; 61(4):598–604.

    PubMed  CAS  Google Scholar 

  198. Holte J, Bergh T, Berne C, Wide L, Lithell H. Restored insulin sensitivity but persistently increased early insulin secretion after weight loss in obese women with polycystic ovary syndrome. J Clin Endocrinol Metab 1995; 80(9):2586–2593.

    Article  PubMed  CAS  Google Scholar 

  199. Andersen P, Seljeflot I, Abdelnoor M, Arnesen H, Dale PO, Lovik A et al. Increased insulin sensitivity and fibrinolytic capacity after dietary intervention in obese women with polycystic ovary syndrome. Metabolism 1995; 44(5):611–616.

    Article  PubMed  CAS  Google Scholar 

  200. Wahrenberg H, Ek I, Reynisdottir S, Carlstrom K, Bergqvist A, Arner P. Divergent effects of weight reduction and oral anticonception treatment on adrenergic lipolysis regulation in obese women with the polycystic ovary syndrome. J Clin Endocrinol Metab 1999; 84(6):2182–2187.

    Article  PubMed  CAS  Google Scholar 

  201. Pasquali R, Gambineri A, Biscotti D, Vicennati V, Gagliardi L, Colitta D et al. Effect of long-term treatment with metformin added to hypocaloric diet on body composition, fat distribution, and androgen and insulin levels in abdominally obese women with and without the polycystic ovary syndrome. J Clin Endocrinol Metab 2000; 85(8):2767–2774.

    Article  PubMed  CAS  Google Scholar 

  202. Randeva HS, Lewandowski KC, Drzewoski J, Brooke-Wavell K, O'Callaghan C, Czupryniak L et al. Exercise decreases plasma total homocysteine in overweight young women with polycystic ovary syndrome. J Clin Endocrinol Metab 2002; 87(10):4496–4501.

    Article  PubMed  CAS  Google Scholar 

  203. Moran LJ, Noakes M, Clifton PM, Tomlinson L, Norman RJ. Dietary composition in restoring reproductive and metabolic physiology in overweight women with polycystic ovary syndrome. J Clin Endocrinol Metab 2003; 88(2):812–819.

    Article  PubMed  CAS  Google Scholar 

  204. Hoeger KM, Kochman L, Wixom N, Craig K, Miller RK, Guzick DS. A randomized, 48-week, placebo-controlled trial of intensive lifestyle modification and/or metformin therapy in overweight women with polycystic ovary syndrome: a pilot study. Fertil Steril 2004; 82(2):421–429.

    Article  PubMed  CAS  Google Scholar 

  205. Jayagopal V, Kilpatrick ES, Holding S, Jennings PE, Atkin SL. Orlistat is as beneficial as metformin in the treatment of polycystic ovarian syndrome. J Clin Endocrinol Metab 2005; 90(2):729–733.

    Article  PubMed  CAS  Google Scholar 

  206. Eid GM, Cottam DR, Velcu LM, Mattar SG, Korytkowski MT, Gosman G et al. Effective treatment of polycystic ovarian syndrome with Roux-en-Y gastric bypass. Surg Obes Relat Dis 2005; 1(2):77–80.

    Article  PubMed  Google Scholar 

  207. Moran LJ, Noakes M, Clifton PM, Wittert GA, Williams G, Norman RJ. Short-term meal replacements followed by dietary macronutrient restriction enhance weight loss in polycystic ovary syndrome. Am J Clin Nutr 2006; 84(1):77–87.

    PubMed  CAS  Google Scholar 

  208. Vigorito C, Giallauria F, Palomba S, Cascella T, Manguso F, Lucci R et al. Beneficial effects of a three-month structured exercise training program on cardiopulmonary functional capacity in young women with polycystic ovary syndrome. J Clin Endocrinol Metab 2007; 92(4):1379–1384.

    Article  PubMed  CAS  Google Scholar 

  209. Palomba S, Giallauria F, Falbo A, Russo T, Oppedisano R, Tolino A et al. Structured exercise training programme versus hypocaloric hyperproteic diet in obese polycystic ovary syndrome patients with anovulatory infertility: a 24-week pilot study. Hum Reprod 2008; 23(3):642–650.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Associate Professor, Departments of Medicine and Physiology/Biophysics, Director, Program of Endocrinology and Metabolism, University of Sherbrooke, Sherbrooke, QC J1H 5N4, Canada

    Jean-Patrice Baillargeon

Authors
  1. Jean-Patrice Baillargeon
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Nadir R. Farid
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jean-Patrice Baillargeon .

Editor information

Editors and Affiliations

  1. The London Endocrine Clinic, 21 Wimpole Street, WIG 8GG, London, UK

    Nadir R. Farid

  2. University of Athens Medical School, Athens, Greece

    Evanthia Diamanti-Kandarakis

Rights and permissions

Reprints and permissions

Copyright information

© 2009 Springer Science+Business Media, LLC

About this chapter

Cite this chapter

Baillargeon, JP., Farid, N.R. (2009). Medical Treatment. In: Farid, N.R., Diamanti-Kandarakis, E. (eds) Diagnosis and Management of Polycystic Ovary Syndrome. Springer, Boston, MA. https://doi.org/10.1007/978-0-387-09718-3_18

Download citation

  • DOI: https://doi.org/10.1007/978-0-387-09718-3_18

  • Published:

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-0-387-09717-6

  • Online ISBN: 978-0-387-09718-3

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation